SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July 2020
Commission File Number: 001-35165
(Translation of registrant's name into English)
19 Hartum Street
Bynet Building, 3rd Floor
Jerusalem, 9777518, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|99.1||BrainsWay to Report Second Quarter 2020 Financial Results and Operational Highlights on August 12, 2020|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: July 29, 2020||/s/ Christopher R. von Jako, Ph.D.|
|Christopher R. von Jako, Ph.D.|
|President and Chief Executive Officer|
BrainsWay to Report Second Quarter 2020 Financial Results and Operational Highlights on August 12, 2020
CRESSKILL, N.J. and JERUSALEM, Israel, July 29, 2020 (GLOBE NEWSWIRE) – BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its second quarter 2020 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 12, 2020. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
Conference Call Dial-In & Webcast Information:
|Date:||Wednesday, August 12, 2020|
|Time:||8:30 AM Eastern Time|
|Israel:||1 809 406 247|
The conference call will be broadcast live and will be available for replay for 30 days on the Company’s website, https://investors.brainsway.com/financial-calendar. Please access the Company’s website at least 10 minutes ahead of the conference call to register.
BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which BrainsWay received marketing authorization from the U.S. Food and Drug Administration (FDA) in 2013 for MDD and in 2018 for OCD. BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.
Forward Looking Statements
Any forward-looking statements are subject to risks and uncertainties such as those described in BrainsWay's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
SVP and Chief Financial Officer